Predicting drug efficacy in chronic low back pain by quantitative sensory tests by Schliessbach, J et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2018
Predicting drug efficacy in chronic low back pain by quantitative sensory
tests
Schliessbach, J; Siegenthaler, A; Bütikofer, L; Vuilleumier, P; Jüni, P; Stamer, U; Arendt-Nielsen, L;
Curatolo, M
Abstract: BACKGROUND Drugs are prescribed for chronic low back pain without knowing in advance
whether a patient will respond to them or not. Quantitative sensory tests (QST) can discriminate patients
according to sensory phenotype, possibly reflecting underlying mechanisms of pain processing. QST may
therefore be a screening tool to identify potential responders to a certain drug. The aim of this study
was to investigate whether QST can predict analgesic effects of oxycodone, imipramine and clobazam
in chronic low back pain. METHODS Oxycodone 15 mg (n = 50), imipramine 75 mg (n = 50) and
clobazam 20 mg (n = 49) were compared to active placebo tolterodine 1 mg in a randomized, double-
blinded, crossover fashion. Electrical, pressure and thermal QST were performed at baseline and after 1
and 2 h. Pain intensity was assessed on a 0-10 numeric rating scale every 30 min for up to 2 h. The ability
of baseline QST to predict pain reduction after 2 h was analysed using linear mixed models. Genetic
variants of drug-metabolizing enzymes and genes affecting pain sensitivity were examined as covariables.
RESULTS No predictor of analgesic effect was found for oxycodone and clobazam. Thermal QST was
associated with analgesic effect of imipramine: patients more sensitive to heat or cold were more likely to
experience an effect of imipramine. Pharmacogenetic variants and pain-related candidate genes were not
associated with drug efficacy. CONCLUSIONS Thermal QST have the potential to predict imipramine
effect in chronic low back pain. Oxycodone and clobazam effects could not be predicted by any of the
selected QST or genetic variants. SIGNIFICANCE Predicting drug efficacy in chronic low back pain
remains difficult. There is some evidence that patients more sensitive to heat and cold pain respond
better to imipramine.
DOI: https://doi.org/10.1002/ejp.1183
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-158366
Journal Article
Accepted Version
Originally published at:
Schliessbach, J; Siegenthaler, A; Bütikofer, L; Vuilleumier, P; Jüni, P; Stamer, U; Arendt-Nielsen, L;
Curatolo, M (2018). Predicting drug efficacy in chronic low back pain by quantitative sensory tests.
European Journal of Pain, 22(5):973-988.
DOI: https://doi.org/10.1002/ejp.1183
1 
 
Predicting Drug Efficacy in Chronic Low-Back Pain by 1 
Quantitative Sensory Tests 2 
Drug prediction by QST in chronic low-back pain 3 
Juerg Schliessbach1,2, Andreas Siegenthaler3, Lukas Bütikofer4, Pascal Vuilleumier1, Peter 4 
Juni5, Ulrike Stamer1, Lars Arendt-Nielsen6, Michele Curatolo7,6 5 
 6 
1Department of Anesthesiology and Pain Medicine, Inselspital, Bern University Hospital, 7 
University of Bern, Switzerland 8 
2Institute of Anesthesiology, University Hospital Zurich, Zürich, Switzerland 9 
3Chronic Pain Management, Lindenhof Hospital, Lindenhof Group Bern, Switzerland 10 
4CTU Bern, and Institute of Social and Preventive Medicine (ISPM), University of Bern, 11 
Switzerland  12 
5Applied Health Research Centre (AHRC), Li Ka Shing Knowledge Institute of St. Michael’s 13 
Hospital, Department of Medicine, University of Toronto, Canada  14 
6Centre of Sensory Motor Interaction SMI, University of Aalborg, Denmark 15 
7Department of Anesthesiology and Pain Medicine, University of Washington, Seattle WA, 16 
USA 17 
- Corresponding author: Juerg Schliessbach, M.D., Institute of Anesthesiology, University 18 
Hospital Zurich, Rämistrasse 100, 8091 Zürich, Switzerland. Phone: +41 44 255 48 35, e-19 
mail: juerg.schliessbach@usz.ch 20 
- Submitted as: Original article 21 
- This study was funded by the Swiss National Science Foundation SNF in the context of 22 
the Special Program for University Medicine SPUM 33CM30_140339. The authors 23 
declare that they have no conflict of interests. 24 
2 
 
- Significance: Predicting drug efficacy in chronic low-back pain remains difficult. There 25 
is some evidence that patients more sensitive to heat and cold pain respond better to 26 
imipramine.  27 
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Introduction 28 
Pharmacotherapy is a mainstay of chronic pain treatment. In current practice, there is no way 29 
to reliably predict the effect of a medication, so that patients are frequently exposed to long 30 
trials of different compounds and experience of side effects in the absence of efficacy.  31 
Quantitative sensory testing (QST) has been investigated in the past years as a tool to 32 
discriminate patients according to sensory phenotype (Edwards et al., 2016; Maier et al., 33 
2010) and to detect differences in nociceptive processing within patients suffering from the 34 
same pain syndrome (Baron et al., 2017). If medications target these different nociceptive 35 
processes in a specific way, QST may have the potential to identify groups of patients that 36 
respond or do not respond to certain pharmacologic treatments. Few investigations have been 37 
conducted in healthy volunteers, neuropathic pain and chronic pancreatitis 38 
 (Attal et al., 2004; Demant et al., 2014; Edwards et al., 2006; Eisenberg et al., 2010; Olesen 39 
et al., 2013; Yarnitsky et al., 2012). These studies identified a selection of QST to predict 40 
treatment response, but the sample sizes were generally small and the results are not 41 
consistent across studies. The most recent evidence (Grosen et al., 2017) showed that opioid 42 
efficacy was predicted by low levels of pain catastrophizing, low pain intensity during cold 43 
pressor stimulus of the hand and certain EEG patterns. The patient population in this study 44 
was very heterogeneous in terms of pain syndrome and pain location. To our knowledge, 45 
there is no specific investigation on the predictive ability of QST for pharmacological 46 
treatment of chronic low-back pain, which is one of the most common and challenging pain 47 
conditions. 48 
There is evidence that chronic low-back pain is associated with sensory hypersensitivity that 49 
extends far beyond the painful region of the back and includes decreased pressure pain 50 
thresholds (Giesecke et al., 2004), as well as enlarged receptive fields and enhanced temporal 51 
summation (Biurrun Manresa et al., 2013) at distant sites. Furthermore, such generalized 52 
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sensory hypersensitivity has been detected in as much as 71-80% of chronic low-back pain 53 
patients (Curatolo et al., 2015). Given its high prevalence, generalized sensory 54 
hypersensitivity is very likely to be associated with some of the pathogenic processes 55 
underlying chronic low-back pain and might therefore be a major determinant of a patient’s 56 
drug responsiveness. 57 
Genetic variations such as polymorphisms of drug metabolizing enzymes affect drug response 58 
as well. A further important question is therefore whether assessing genetic polymorphisms 59 
before initiating pharmacological treatment can explain different drug effects and thus help 60 
selecting the appropriate therapeutic strategy for individual patients. 61 
The aim of the present study was to investigate whether generalized sensory hypersensitivity 62 
measured by QST could predict the analgesic effect of three different drugs in chronic low-63 
back pain: the µ-opioid agonist oxycodone, the tricyclic antidepressant imipramine, and the 64 
benzodiazepine clobazam. These drugs were chosen in order to cover multiple modes of 65 
analgesic action. Oxycodone is a potent agonist at peripheral and central opioidergic 66 
pathways, imipramine is a modulator of noradrenergic and serotonergic neurotransmission in 67 
the central nervous system, and clobazam modulates spinal nociceptive inhibitory GABA-68 
ergic pathways (Schliessbach et al., 2017; Vuilleumier et al., 2013; Zeilhofer et al., 2009).  69 
Polymorphisms of pain-related genes were examined as co-factors. The -opioid receptor 70 
variant A118G (Chou et al., 2006) was examined as a possible factor affecting the effect of 71 
oxycodone. COMT (catechyl-o-methyltransferase) (Diatchenko et al., 2005), GCH-1 (GTP-72 
Cyclohydroxylase) (Campbell et al., 2009) and the potassium channel subunit KCNS1 73 
(Costigan et al., 2010) are known for influencing pain perception. Finally, the major 74 
metabolic pathways for the three drugs were investigated: CYP2C19, which is involved in 75 
imipramine and clobazam metabolism, CYP2D6 for imipramine and oxycodone metabolism, 76 
and CYP3A4 that mediates oxycodone and clobazam metabolism (Giraud et al., 2004; Kosaki 77 
et al., 2004).   78 
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Methods 79 
Setting 80 
This randomized placebo-controlled trial in consecutive patients with chronic low-back pain 81 
was carried out at the University Department of Anesthesiology and Pain Medicine, 82 
Inselspital Bern, Switzerland. The study was approved by the local ethics committee (KEK 83 
213-09), registered with clinicaltrials.gov (NCT01179828) and strictly followed good clinical 84 
practice guidelines and the Helsinki declaration. The study protocol has been published 85 
previously (Siegenthaler et al., 2015). All participants gave written informed consent prior to 86 
inclusion. 87 
Patients 88 
Consecutive patients aged between 18 and 80 years with chronic low-back pain of at least 3 89 
months duration were recruited by advertisement in local newspapers and from the outpatient 90 
pain clinic of our department. Exclusion criteria were pain intensity at rest <3 on the 91 
numerical rating scale (NRS) at the time of testing (whereby 0 = no pain and 10 = worst pain 92 
imaginable), suspected radicular pain (as defined by leg pain associated with an MRI finding 93 
of a herniated disc or foraminal stenosis), signs or suspicion of neurological dysfunction at the 94 
tested sites, pregnancy (as assessed by pregnancy test in women of fertile age), breast feeding, 95 
ongoing treatment with an antidepressant, opioid or anticonvulsant, intake of centrally active 96 
substances, drug or alcohol abuse, known allergy or pharmacological contraindications to any 97 
of the tested drugs, systemic inflammatory or rheumatologic disease, and major depression 98 
(Beck Depression Inventory short form score >9). Current analgesic medication had to be 99 
stopped one week before the first experiment. Only acetaminophen and ibuprofen were 100 
allowed as rescue medication until 24 hours before the experiment. Patients unable to stop 101 
their analgesic regimen were not recruited. 102 
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Study medication 103 
A single oral dose of imipramine 75 mg or oxycodone 15 mg or clobazam 20 mg were each 104 
compared to active placebo in a cross-over fashion. Because all of the three drugs are likely to 105 
be associated with minor central side effects, such as dizziness or sedation, the anti-106 
cholinergic compound tolterodine was chosen as an active placebo. It is usually prescribed for 107 
hyperactive bladder syndrome and causes some sedation and dry mouth, but is devoid of 108 
analgesic effects. The recommended starting dose is 2 mg twice a day, which can be 109 
decreased to 1 mg twice a day. In order to minimize the likelihood of excessive side effects, a 110 
dose of 1 mg was chosen for this study. A minimal wash-out period of one week between 111 
sessions was ensured. 112 
After completion of one experiment, patients were allowed to cross over to one or both of the 113 
remaining drugs, which were each compared to a new placebo session again. Therefore, those 114 
patients who took part in all 3 drug tests had a maximum of 6 testing sessions (each of the 115 
three drugs vs. placebo). The drugs were administered as identical-looking red gelatin 116 
capsules in random order and in a fasting state. Blinding and randomization were provided by 117 
the hospital pharmacy. If a patient was re-enrolled to another drug, his sequence number was 118 
announced to the pharmacy. Thus, the pharmacist ensured that the patient was not randomized 119 
twice to the same drug. 120 
QST 121 
Quantitative sensory testing was performed at baseline as well as one and two hours after 122 
drug administration. A complete series of training measurements was performed half an hour 123 
before baseline assessments, at the same locations and in the same sequence as the subsequent 124 
definite measurements, in order to familiarize patients with the procedure. All tests were 125 
performed at the more painful body side. In case of bilateral or midline pain, the side was 126 
randomly selected. 127 
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The test battery consisted of pressure pain thresholds, meant to assess mechanical 128 
nociception, electrical pain thresholds which are thought to bypass peripheral nociceptors and 129 
directly stimulate nerve fibers, temporal summation thresholds which reflects central 130 
integration of nociceptive stimuli by wide dynamic range neurons, as well as heat and cold 131 
pain tests assessing thermally-induced nociceptive processes. The rationale for the multiple 132 
testing is the fact that responses to different stimulus modalities reflect different aspect of 133 
nociceptive processes (Neziri et al., 2011). Conditioned pain modulation was tested as a 134 
feature of endogenous pain inhibitory capacity. Tests were always performed in the order as 135 
presented. 136 
Pressure pain detection and tolerance thresholds (PPDT and PPTT)  137 
PPDT and PPTT were recorded at the pulp of the 2nd toe using an electronic pressure 138 
algometer (Somedic AB, Horby, Sweden) with a probe tip of 1 cm2. Pressure was increased at 139 
a rate of 30 kPa/s up to a maximum of 1000 kPa. The subject stopped the measurement by 140 
pressing a button when the pressure sensation turned to pain (PPDT) and when the painful 141 
sensation became intolerable (PPTT), respectively. Both PPDT and PPTT were recorded in 142 
intervals of 1 minute between measurements. The 2nd toe was chosen because large 143 
differences in pain sensitivity between pain patients and healthy controls can be detected there 144 
(Banic et al., 2004) and because it is distant from the painful site, therefore reflecting 145 
generalized excitability of the nervous system. 146 
Electrical single and repeated pain thresholds (ESPT and ERPT)  147 
ESPT and ERPT were performed using a computer-controlled constant current stimulator 148 
(Digitimer Ltd, Welwyn Garden City, UK). Bursts of five 1 ms square wave impulses within 149 
25 ms (perceived as one single stimulus) were delivered via 2 Ag-AgCl electrodes placed in 150 
the innervation area of the sural nerve, directly below the lateral malleolus. The current 151 
intensity was increased from 1 mA in steps of 0.5 mA until the sensation was rated as painful 152 
(ESPT). For ERPT, the stimuli were repeated five times at a frequency of 2 Hz. Current 153 
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intensity of all 5 stimuli was increased in steps of 0.5 mA until the last 2-3 stimuli were 154 
perceived as painful, indicating temporal summation threshold. This measure of ESPT has 155 
one of the best positive predictive values to discriminate low-back pain patients from healthy 156 
controls (Neziri et al., 2012). 157 
Electrical train of twenty 158 
The arithmetical mean of three ERPT assessments at baseline was used to deliver 20 identical 159 
stimuli over 10 seconds with a frequency of 2 Hz. This stimulus intensity remained constant 160 
over the two subsequent measurements at 60 and 120 minutes. Subjects rated the maximal 161 
and final pain intensity during this stimulation on a 0-10 NRS. A decrease in pain intensity in 162 
the subsequent measurements would be indicative of an analgesic effect. A decrease from 163 
maximal to final pain intensity during the 20 stimulations was considered a feature of pain 164 
habituation that might be due to activation of inhibitory neuronal circuits. An increase in pain 165 
intensity, on the other hand, was suggestive of pain-facilitatory mechanisms. Patients whose 166 
pain ratings decreased during the train-of-twenty stimulation (T20) were defined as T20-167 
decreasers in contrast to those with constant or increasing pain ratings over all 20 stimuli. 168 
Temperature pain thresholds (HPDT, HPTT, CPDT)  169 
Temperature pain thresholds were assessed using a thermode (TSA II, Medoc, Ramat Yishai, 170 
Israel) with a probe surface of 3x3 cm. All measurements started at 30.0°C, the rate of 171 
temperature change was 1°C/s. Subjects stopped the measurements by pressing a button when 172 
the warm sensation turned to pain (HPDT) or when the pain became intolerable (HPTT) or 173 
when the cold sensation started to become painful (CPDT). In any case, the measurements 174 
were stopped at a temperature of 50.5°C for HPTT or 0°C for CPDT, respectively. 175 
Measurements were made first at the lateral aspect of the lower leg (dermatome L5), and then 176 
at the radial surface of the proximal forearm (dermatome C6). Because HPTT and CPDT 177 
measurements were truncated at 50.5°C and 0°C, respectively, the results were dichotomized 178 
for statistical modelling according to whether patients reached the limit or not.  179 
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Conditioned pain modulation (CPM) 180 
CPM was assessed using the cold pressor test at the hand contralateral to the tested side. 181 
Subjects immersed their hand in ice saturated water (1.5±1°C), until the cold pain reached an 182 
intensity of 7/10 on the NRS. Five electrical stimulations at an intensity 1.2 times stronger 183 
than the previously measured ERPT were delivered three times in intervals of 10 seconds and 184 
rated by the subject on a 0-10 NRS. This was performed before and during the cold pressor 185 
test. The percent decrease in pain rating with electrical stimulation during the cold pressor test 186 
was calculated as indication measure of CPM. Furthermore, the time until cold pressor pain 187 
reached 7/10 NRS was recorded. For all tests but CPM, triplicate measurements were 188 
recorded.  189 
Outcome measures 190 
Intensity of low-back pain in the supine position and after sitting for 10 minutes was assessed 191 
on a 0-10 NRS at baseline and in intervals of 30 minutes up to 2 hours after drug intake. This 192 
was considered sufficient time given that oxycodone starts to be effective 1 hour after intake 193 
(Ordonez Gallego et al., 2007) and clobazam peaks around 2 hours after intake (Greenblatt et 194 
al., 1983). For imipramine, major anti-nociceptive effects were detected already 90 minutes 195 
after intake (Bromm et al., 1986). Patients with ≥30% pain reduction were classified as drug 196 
responders. The patients’ global impression of change scale (PGIC) (Dworkin et al., 2005) 197 
was assessed on a 7 point scale ranging from “1 = very much improved” over “4 = no change” 198 
to “7 = very much worse”, in intervals of 30 minutes, starting 30 minutes after drug 199 
administration. Patients remained in the supine position during the whole experiment, except 200 
for those 10-min intervals when sitting pain was assessed. Reading newspapers or magazines 201 
was allowed between the measurements. 202 
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Descriptive variables 203 
The following descriptive variables were assessed on a questionnaire before the first 204 
experiment: age, sex, body mass index (BMI), pain duration in years, history of surgery due 205 
to the painful condition, average pain intensity during the last 24 hours on a 0-10 NRS, pain-206 
related life interference from the multidimensional pain inventory (MPI) (Kerns et al., 1985), 207 
catastrophizing scale (Keefe et al., 1989) and Beck Depression Inventory (BDI) (Poole et al., 208 
2009). 209 
Genotyping 210 
Genetic analyses were performed for the following candidate genes involved either in drug 211 
metabolism or in pain perception: CYP2C19 (involved in imipramine and clobazam 212 
metabolism), CYP2D6 (imipramine and oxycodone metabolism), CYP3A4 (oxycodone and 213 
clobazam metabolism) (Giraud et al., 2004; Kosaki et al., 2004), the -opioid receptor variant 214 
A118G (oxycodone binding site) (Chou et al., 2006), COMT (catechyl-o-methyltransferase 215 
with 3 categories: low, average or high pain sensitivity) (Diatchenko et al., 2005); GCH-1 216 
(GTP-Cyclohydroxylase with no, one or two pain-protective alleles) (Campbell et al., 2009) 217 
and the potassium channel subunit KCNS1 (low, medium and high pain risk for zero, one or 218 
two mutant alleles, respectively) (Costigan et al., 2010). Genotyping was performed using 219 
real-time polymerase chain reaction (PCR) and identification of specific variants by means of 220 
melting curve analysis. For CYP2D6, translation of genotypes into a qualitative measure of 221 
phenotype was made according to Gaedigk’s system of “activity scores” (Gaedigk et al., 222 
2008): alleles *3,*4,*5,*6,*7, and *8 were assigned a value of 0, alleles *10 and *41 a value 223 
of 0.5, the wild type (wt) allele a value of 1, and wtxN (representing multiplication of the wt 224 
allele) a value of 2. The sum of the values assigned to each single allele resulted in a CYP2D6 225 
activity score. Activity scores of 0 correspond to poor metabolizers (PM), scores of 0.5-1 to 226 
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intermediate metabolizers (IM); scores of 1.5-2 to extensive metabolizers (EM) and scores of 227 
3 to ultra-rapid metabolizers (UM). 228 
Statistical analyses 229 
The predictive effects of individual baseline variables including descriptives, genetics and 230 
baseline QST measures were analyzed using linear mixed model with pain intensity (NRS) 231 
after 120 minutes as dependent variable. Baseline NRS, type of drug (verum vs. placebo), 232 
treatment order (i.e. whether verum or placebo session was first), a baseline variable (e.g. 233 
QST measure) and its interaction with the type of drug were used as explanatory variables. 234 
Positively skewed QST measures (PPDT, PPTT, ESPT, ERPT, time in ice water) were log-235 
transformed. All continuous explanatory variables were standardized and the z-scores were 236 
used in the analyses. To account for intra-subject correlation, a random intercept was added 237 
for each subject. The models were fitted via maximum likelihood and likelihood ratio tests 238 
were used to compare models with and without interaction. P-values were adjusted according 239 
to the Benjamini-Hochberg procedure to control for false-positive results due to the high 240 
number of analyzed baseline variables (Benjamini and Hochberg 1995). Adjusted p-values 241 
represent the false discovery rate, i.e. the proportion of false discoveries among all significant 242 
findings. A false discovery rate of 10% was deemed acceptable for this analysis, thus findings 243 
with an adjusted p<0.1 were considered significant. 244 
Sample size calculation was performed assuming a correlation of pain scores across active 245 
and placebo phase within a patient of 0.65, a prevalence of treatment responders of 40% and a 246 
difference in NRS of 2.5 between drug and placebo. Using these parameters, analyzing 50 247 
patients per drug would allow to detect an interaction between treatment effect and QST at a 248 
two-sided alpha-level of 5% with a power of 90%. 249 
Statistical analysis were done in Stata 14 (StataCorp, College Station, TX) and R (R Core 250 
Team, Vienna, Austria).  251 
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Results 252 
Here we present the result pertaining to the aim of the present paper, specifically the ability of 253 
baseline QST to predict medication efficacy. Separate papers are under construction or have 254 
been published that address the effects of medications on pain and QST. The results of these 255 
analyses are mentioned only briefly in the present paper. 256 
Results tables display the interaction of baseline parameters with the effect of each specific 257 
drug. A positive interaction term indicates a positive influence of the variable on drug effect, 258 
compared to placebo. Z-transformation makes the interaction term independent from the unit 259 
of measure (e.g. kPa, mA, °C). Equal interaction terms thus indicate equal effects of the QST 260 
parameter on drug response. For example, an interaction term of -0.5 indicates a pain decrease 261 
of 0.5 points on the NRS per one standardized unit increase of the covariate. P-values are 262 
from likelihood ratio tests comparing models with and without interaction.  263 
Oxycodone 264 
Fifty patients (26 females) were tested in the oxycodone arm (mean age 55 years, SD 15.2). 265 
A significant analgesic effect on low-back pain and anti-nociceptive effects on almost all QST 266 
parameters were observed. Supine pain decreased from 3.7 (95%-CI 3.4 to 4.1) at baseline to 267 
1.5 (1.1 to 2.0) with oxycodone and from 4.0 (3.5 to 4.5) to 3.0 (2.4 to 3.5) with placebo after 268 
2 hours (p<0.001). There were 36 vs. 22 responders in the verum vs. placebo session, 269 
respectively. Sitting pain decreased from 4.0 (3.6 to 4.4) at baseline to 1.6 (1.2 to 2.0) with 270 
oxycodone and from 4.4 (4.0 to 4.8) to 2.9 (2.4 to 3.3) with placebo after 2 hours (p<0.001). 271 
There were 44 vs. 25 responders in the verum vs. placebo session, respectively. More detailed 272 
results are addressed in a separate publication (Schliessbach et al., Scand J Pain, in press). 273 
Only for the supine position, significant interactions of clinical variables with oxycodone 274 
effect were found. Average pain in the last 24 hours (interaction term 0.50, 95%-CI 0.16 to 275 
0.84), catastrophizing score (interaction term 0.45, 95%-CI 0.06 to 0.84) and BDI (interaction 276 
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term 0.21, 95%-CI -0.00 to 0.42) showed potential positive influences on the effect of 277 
oxycodone after 120 minutes (p=0.005, 0.027 and 0.06, respectively). However, none of these 278 
variables remained statistically significant after p-value adjustment for multiple testing 279 
(adjusted p=0.20, 0.52, 0.74, respectively). Neither genetics nor the baseline sensory tests 280 
were associated with the effect of oxycodone (supplementary tables S1 and S2). 281 
Imipramine 282 
A total of 50 patients underwent the imipramine experiment (32 females, mean age 54.4 283 
years, SD 17.3). The effect of imipramine was at no time point significantly different from 284 
placebo, neither in the sitting nor in the supine position. Pain intensity in supine position 285 
decreased from 4.2 (95%-CI 3.8 to 4.6) to 2.6 (2.1 to 3.2) after 2 hours in the imipramine arm 286 
and from 4.0 (3.5 to 4.5) to 2.5 (2.0 to 3.1) in the placebo arm (treatment effect 0.02 (-0.51 to 287 
0.56), p=0.95). There were 27 responders in the verum vs. 31 responders in the placebo 288 
session. Pain intensity in sitting position decreased from 4.7 (4.1 to 5.1) to 2.9 (2.3 to 3.5) 289 
after 2 hours in the imipramine arm and from 4.2 (3.8 to 4.6) to 2.7 (2.2 to 3.2) in the placebo 290 
arm (treatment effect 0.16 (-0.28 to 0.6), p=0.74). There were 30 responders in the verum vs. 291 
27 responders in the placebo session. 292 
Although imipramine had no overall effect on low back pain, the baseline thermal thresholds 293 
significantly interacted with the effect of imipramine on pain intensity compared to placebo 294 
after 120 minutes in the sitting and – slightly less – in the supine position. Specifically, 295 
patients more sensitive to heat and cold pain experienced a greater reduction of their low-back 296 
pain by imipramine. Interaction terms and p-values are summarized in tables 1 and 2; 297 
treatment effects are displayed by Forest plots in figures 1 and 2. 298 
Further possible interactions with imipramine-effect on low-back pain were found for the µ-299 
opioid receptor A118G allele (interaction term 0.84, 95%-CI 0.03 to 1.66, p=0.047, only in 300 
sitting position), the COMT high-pain-sensitivity genotype (1.51, -0-09 to 3.11, p=0.05, only 301 
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in sitting position), PPDT (-1.19, -2.23 to -0.14, p=0.03, only in sitting position), but they 302 
remained no longer significant after correction for multiple testing. Average pain intensity 303 
during 24 hours before the experiment (-0.34, -0.57 to -0.11, p=0.005, p=0.07 after 304 
Benjamini-Hochberg correction) showed some trend for interaction with drug effect, but only 305 
in the supine position. 306 
Clobazam 307 
Fifty patients were included in the clobazam arm, one of which did not show up for the 308 
second test session. Forty-nine patients were therefore analyzed (29 females, mean age 54.3 309 
years, SD 15.8). A significant analgesic effect was found in the supine, but not in the sitting 310 
position (treatment effect compared to placebo: 0.7, 95%-CI 0.2 to 1.1, p=0.003), which is the 311 
object of a separate publication (Schliessbach et al., 2017). For supine pain, there were 29 312 
responders in the verum session vs. 20 in the placebo session. For sitting pain, there were 28 313 
responders in the verum session vs. 25 in the placebo session. 314 
Baseline heat pain thresholds interacted with clobazam effect after 120 minutes in sitting but 315 
not in supine position (table 3 and supplementary table S3). Specifically, patients with 316 
baseline HPTT at limit (i.e. relatively insensible to heat) responded better to placebo, whereas 317 
more heat-sensitive patients had a better effect of clobazam. Treatment effects are shown in 318 
figure 3. In supine position, significant interaction was only found for the KCNS1 gene 319 
mutation, with the medium-pain-risk genotype pointing towards a more negative influence 320 
and the high-pain-risk genotype towards a positive influence on the effect of clobazam than 321 
the low-pain-risk genotype. 322 
Genotyping 323 
Genotyping was successfully performed in all 90 participants except for the rs4680 of the 324 
COMT gene and the CYP2D6*41 single-nucleotide polymorphism, each of which had 1 325 
missing value. The results corresponded well with what was expected from a middle 326 
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European population. All but the CYP2D6*3A polymorphism were well within the Hardy-327 
Weinberg equilibrium. Detailed allele frequencies are presented in supplementary table S4. 328 
False discovery rate 329 
After adjustment of p-values according to the Benjamini-Hochberg procedure, significant 330 
interactions of baseline variables and drug effect were only found in the imipramine 331 
experiment. For imipramine in supine position, the following descriptive variables remained 332 
significant (with 10% potential false discoveries among them): dichotomized baseline HPTT 333 
(leg and arm) and average pain in the last 24 hours. For imipramine in sitting position, the 334 
following variables remained significant (with 10% potential false discoveries among them): 335 
dichotomized baseline HPTT and CPDT (both leg and arm), both HPDT at leg and arm, 336 
CPDT at leg and arm, as well as HPTT at the arm. Among these 12 significant findings, 1-2 337 
may be potential false discoveries. 338 
  339 
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Discussion 340 
This study found a pronounced analgesic effect of oxycodone on low-back pain, but no 341 
evidence for any of the baseline characteristics to predict that effect. For imipramine, the data 342 
suggest that thermal sensory tests predict its effect: patients who are more sensitive to heat or 343 
cold pain had a better effect of imipramine than patients who were less sensitive to these 344 
modalities. While an analgesic effect was found for clobazam, no predictor could be 345 
identified.  346 
Oxycodone 347 
Oxycodone is a strong opioid with well documented analgesic effects in various acute and 348 
chronic pain conditions. Its short-term effectiveness on chronic low-back pain is therefore not 349 
surprising (Chaparro et al., 2013). The fact that average pain during the past 24 hours, 350 
catastrophizing and BDI were found to interact with oxycodone effect only in supine position 351 
suggests that these may be chance findings. Otherwise, there should have been at least a trend 352 
for these interactions in the sitting position as well. After correction for multiple testing, these 353 
variables were no longer significantly associated with drug effect. Yet, the study by Grosen et 354 
al. (Grosen et al., 2017) identified pain catastrophizing as a significant predictor for opioid 355 
efficacy. It must be noted, however, that their study population included patients with various 356 
pain syndromes, including head, neck and other musculoskeletal as well as neuropathic pain 357 
patients.  358 
Of particular interest is the fact that not even the µ-opioid receptor A118G mutation 359 
significantly influenced the analgesic effect of oxycodone. This may partly be due to 360 
insufficient sample size, with no homozygous and only 16 heterozygous carriers of the mutant 361 
allele among the 50 patients. Another explanation may be that the influence of the genetic 362 
variant varies with the type of opioid used. There is evidence that carriers of the mutant G 363 
allele seem to have less analgesic effect of morphine (Campa et al., 2008), but in a similar 364 
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investigation for oxycodone such an association could not be demonstrated (Zwisler et al., 365 
2012). 366 
As to the prediction of oxycodone effect by QST, there was a previous study in healthy 367 
volunteers that found high basal heat pain thresholds and high degrees of temporal summation 368 
to be associated with greater oxycodone analgesia (Eisenberg et al., 2010). Neither of those 369 
parameters was found to influence oxycodone effect in the present study. These differing 370 
results cannot easily be compared, because outcome measures are not the same in pain 371 
patients and in volunteers and the study on healthy volunteers had no placebo control. 372 
Another possible explanation may be the quite unanimous response to the drug in our study 373 
sample, with up to 88% of patients having significant pain reduction. The number of patients 374 
experiencing minimal or no effect may therefore have been too small to allow for sufficient 375 
discrimination between responders and non-responders. 376 
Imipramine 377 
The most consistent interactions were found in the imipramine experiment, where almost all 378 
thermal tests were associated with the effect of the drug. This was most pronounced for the 379 
dichotomized CPDT and HPTT and remained significant even after p-value adjustment for 380 
multiple testing. In particular, patients who reached the limits without having pain were less 381 
likely to experience a drug effect, whereas patients who did not reach the limits (i.e. who were 382 
more sensitive to heat and cold pain) experienced greater drug effect. The same tendency 383 
could be observed when thermal QST were analyzed as continuous variables, but less 384 
pronounced and only for pain in the sitting position.  385 
Existing literature is mainly based on neuropathic pain patients, but has repeatedly found 386 
thermal pain thresholds to predict analgesic effects: Holbech et al. found that neuropathic pain 387 
patients with gain-of-function phenotype (including thermal allodynia) were more likely to 388 
benefit from imipramine (Holbech et al., 2016), and thermal pain thresholds were identified as 389 
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predictors of drug effect in post-herpetic neuralgia and traumatic nerve injury (Attal et al., 390 
2004; Edwards et al., 2006).  391 
It is increasingly recognized that there may be a neuropathic component in low-back pain 392 
patients even in the absence of typical radicular pain. However, no gold-standard tests exists 393 
to diagnose this reliably (Baron et al., 2016). A neuropathic component in our patient 394 
population could partly explain the observed results. 395 
Clobazam 396 
In the clobazam arm, the dichotomized HPTT were found to influence drug effect on pain in 397 
the sitting position in a similar way than for imipramine. The results suggested that patients 398 
who were more sensitive to heat pain (i.e. HPTT not at limit) experienced a greater analgesic 399 
effect of clobazam in sitting position. However, these results were no longer significant after 400 
correction for multiple testing, so we cannot rule out that they are chance findings. For pain in 401 
the supine position, where an analgesic effect was detected, only KCNS1 showed a significant 402 
interaction with drug effect. According to Costigan et al. (Costigan et al., 2010) the presence 403 
of one or two valine alleles confers an additive effect on pain threshold. The present results, 404 
however, were somewhat contradictory because homozygous (i.e. one valine allele) and 405 
heterozygous (i.e. both valine alleles) patients experienced opposite clobazam effects 406 
compared to the wild type. This was no longer significant after p-value correction and may 407 
therefore be a false-positive finding. Unfortunately, there is no existing literature specifically 408 
addressing clobazam in low-back pain to compare these findings to. 409 
Implications of results 410 
The search for parameters predicting the response to analgesic treatment has been of great 411 
interest in the past few years. Existing studies have addressed various forms of chronic pain. 412 
For instance, duloxetine for diabetic neuropathy seems to be more effective in patients with 413 
poor baseline CPM (Yarnitsky et al., 2012). Patients with chronic pancreatitis responded 414 
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better to treatment with pregabalin when they were hypersensitive to electrical stimulation 415 
within the pancreatic dermatome Th10 (Olesen et al., 2013). As mentioned above, heat pain 416 
thresholds predicted opioid analgesia in patients with post-herpetic neuralgia (Edwards et al., 417 
2006). It has been proposed that “dynamic” QST (e.g. temporal summation or CPM) are more 418 
suitable than “static” paradigms (i.e. simple pain threshold measurements) to predict drug 419 
efficacy and to distinguish “pro-nociceptive” and “anti-nociceptive” pain states (Yarnitsky et 420 
al., 2012). However, for the prediction of opioid efficacy, both static and dynamic tests seem 421 
to be useful (Eisenberg et al., 2010). Of note, static QST probably have a better long-term 422 
reliability than dynamic tests (Marcuzzi et al., 2017). In this regard, caution must be taken not 423 
to overrate experimental findings that solely rely on one-time assessments of dynamic QST. 424 
To the best knowledge of the authors, no study has so far investigated the predictive ability of 425 
QST in chronic low-back pain. In this respect, the present study adds important information to 426 
the existing evidence, as chronic low-back pain is one of the most common painful disorders 427 
in clinical practice.  428 
The strict selection criteria of patients give us some confidence that we have enrolled a 429 
sample of individuals with relatively homogeneous pathophysiology. Hypothesizing that the 430 
majority of our patients had mainly nociceptive and not neuropathic pain might explain why 431 
oxycodone but not imipramine showed a profound analgesic effect. Oxycodone has a specific 432 
pharmacologic target at the µ-opioid receptor which may lead to pain relief in most patients 433 
regardless of their QST-profile. Conversely, imipramine with its multiple pharmacologic 434 
actions tended to relieve pain only in a subgroup of more heat- and cold-sensitive patients. 435 
The question remains whether these patients had a certain neuropathic component in the 436 
pathogenesis of their pain and therefore responded better to imipramine, or whether their 437 
relative thermal hypersensitivity was an expression of a specific nociceptive mechanism in 438 
which imipramine was particularly effective. It is tempting to speculate that these patients had 439 
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some sort of spinal hypersensitivity that responded well to imipramine-mediated modulation 440 
of inhibitory noradrenergic and serotonergic neural pathways. 441 
Most studies about prediction of drug response by QST were conducted in neuropathic pain. 442 
Unlike low-back pain patients, neuropathic pain patients display a broad clinical picture of 443 
sensory alterations of thermal, mechanical or vibratory perception, alone or in combination, 444 
with gain or loss of function. According to this variety, three distinct phenotypic groups were 445 
identified (Baron et al., 2017): (1) patients with predominant sensory loss, (2) patients with 446 
heat hyperalgesia and (3) patients with mechanical hyperalgesia. The authors hypothesized 447 
that group 1 might best be treated with oral opioids, group 2 with oxcarbazepine or capsaicin 448 
and group 3 with gabapentinoids or lidocaine. These findings are promising, but need to be 449 
substantiated in future prospective studies. In the light of the present results, it seems unlikely 450 
that similar considerations pertain to chronic low-back pain, most probably because chronic 451 
low-back pain patients do not show such clearly distinguishable sensory phenotypes. 452 
Conceivably, the broader the spectrum of detectable sensory phenotypes, the greater the 453 
chances of identifying one particular phenotype that responds to a given drug. However, even 454 
in these cases, the statistical models could barely account for more than about 20% of 455 
observed variability (Edwards et al., 2006). Unfortunately, no two studies used the same QST 456 
paradigms, drugs or pain syndromes. Because of this methodologic heterogeneity, no firm 457 
conclusion about the ability of QST to predict analgesic response can be made at the time 458 
(Grosen et al., 2013). 459 
Strengths and limitations 460 
The present study is the first one to investigate the ability of QST to predict drug response in a 461 
fairly homogeneous and sufficiently large population of patients with chronic low-back pain. 462 
The QST protocol was extensive and included mechanical, thermal and electrical pain 463 
threshold as well as dynamic paradigms such as CPM and temporal summation, therefore 464 
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reflecting a wide range of nociceptive processes. However, other modalities could be included 465 
provide complementary information. Three drugs with different modes of action were studied: 466 
oxycodone as a clearly defined µ-opioid agonist, imipramine with multiple pharmacologic 467 
actions such as sodium channel blockade and central noradrenergic and serotonergic effects, 468 
and clobazam as a modulator of spinal inhibitory GABA-ergic transmission. 469 
A large number of statistical tests had to be performed as a consequence of the extensive 470 
protocol, bearing the risk of chance findings. The few statistically significant results have 471 
therefore to be interpreted in this context, although the data were corrected for multiple 472 
testing. A multivariable model with a combination of predictors was not within the scope of 473 
this study and interactions between predictors cannot be excluded. The fact that some patients 474 
were randomized to more than one drug may introduce the risk of a selection bias. Finally, 475 
this was a single-dose study with an observation time of 2 hours, intended to investigate 476 
immediate effects from a mechanistic point of view. Immediate effects could indeed be 477 
demonstrated for oxycodone and clobazam. Unfortunately, no immediate effects were seen 478 
for imipramine. This does not imply that imipramine is ineffective in low-back pain, as most 479 
previous studies investigating tricyclic antidepressants used treatment periods of several 480 
weeks.  481 
Conclusion 482 
This is the first study to address the ability of QST to predict drug effect in chronic low-back 483 
pain. None of the selected QST measures could be identified as predictor of analgesic effect 484 
of oxycodone or clobazam. We found evidence that patients more sensitive to heat and cold 485 
pain respond better to imipramine. None of the candidate genes involved in pain sensitivity or 486 
drug metabolism seemed to be a predictor of drug effect. 487 
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Table 1 647 
 
No. of 
observations 
Interaction with drug 
effect 
P-value from LR 
test 
Adjusted p-
value 
Sex 98  0.15 0.58 
    male 36 0 (Ref)   
    female 62 -0.69 (-1.62 to 0.23)   
Operated due to pain 96  0.59 0.72 
    no 77 0 (Ref)   
    yes 19 -0.31 (-1.42 to 0.81)   
KCNS1 98  0.76 0.83 
    low pain risk 21 0 (Ref)   
    medium pain risk 56 0.04 (-1.04 to 1.13)   
    high pain risk 21 -0.36 (-1.68 to 0.95)   
GCH1 98  0.17 0.58 
    no pain protect 74 0 (Ref)   
    one pain protect 18 1.00 (-0.07 to 2.06)   
    both pain protect 6 0.67 (-1.09 to 2.44)   
OPRM1 98  0.30 0.72 
    homozygous wild type 66 0 (Ref)   
    1/2 mutant allele 32 0.49 (-0.43 to 1.41)   
COMT 98  0.58 0.72 
    low pain sensitivity 12 0 (Ref)   
    average pain sensitivity 76 0.37 (-1.03 to 1.78)   
    high pain sensitivity 10 0.96 (-0.87 to 2.79)   
2D6 98  0.55 0.72 
    poor metabolizer 6 0 (Ref)   
    intermediate metabolizer 39 0.39 (-1.53 to 2.31)   
    extensive metabolizer 51 0.59 (-1.24 to 2.42)   
    ultrarapid metabolizer 2 2.42 (-0.97 to 5.80)   
2C19 98  0.52 0.72 
    poor metabolizer 2 0 (Ref)   
    intermediate metabolizer 20 1.82 (-1.33 to 4.97)   
    extensive metabolizer 76 1.76 (-1.26 to 4.77)   
3A5 98  0.09 0.44 
    low expressors 81 0 (Ref)   
    normal/high expressors 17 0.99 (-0.15 to 2.13)   
T20 decreasers 98  0.32 0.72 
    No decrease 89 0 (Ref)   
    Decrease 9 0.92 (-0.86 to 2.69)   
Baseline HPTT (leg) at limit 97  0.004 0.07 
    No 58 0 (Ref)   
    Yes 39 -1.34 (-2.23 to -0.46)   
Baseline HPTT (arm) at limit 91  0.003 0.07 
    No 70 0 (Ref)   
    yes 21 -1.59 (-2.62 to -0.56)   
Baseline CPDT (leg) at limit 97  0.71 0.82 
    no 52 0 (Ref)   
    yes 45 -0.18 (-1.15 to 0.78)   
Baseline CPDT (arm) at limit 91  0.06 0.42 
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    no 65 0 (Ref)   
    yes 26 -1.00 (-2.01 to 0.01)   
Age 98 0.08 (-0.34 to 0.51) 0.70 0.82 
BMI 98 -0.19 (-0.62 to 0.24) 0.38 0.72 
Pain duration 98 -0.38 (-0.80 to 0.03) 0.08 0.42 
Average pain in the last 24h 98 -0.59 (-0.99 to -0.19) 0.005 0.07 
Impairment of daily life 98 -0.18 (-0.61 to 0.26) 0.43 0.72 
Catastrophizing score 98 -0.26 (-0.69 to 0.17) 0.24 0.62 
Beck Depression Index 98 0.12 (-0.32 to 0.57) 0.59 0.72 
CPM 97 -0.21 (-0.69 to 0.26) 0.38 0.72 
PPDT 98 0.03 (-0.42 to 0.48) 0.90 0.92 
PPTT 98 0.21 (-0.26 to 0.67) 0.39 0.72 
ESPT 98 -0.06 (-0.54 to 0.41) 0.79 0.84 
ERPT 98 -0.02 (-0.50 to 0.46) 0.93 0.93 
Iwsec 97 -0.16 (-0.60 to 0.28) 0.48 0.72 
HPDT (leg) 97 -0.57 (-1.03 to -0.11) 0.020 0.19 
HPDT (arm) 91 -0.33 (-0.81 to 0.15) 0.18 0.58 
HPTT (leg) 97 -0.29 (-0.75 to 0.17) 0.22 0.61 
HPTT (arm) 91 -0.30 (-0.77 to 0.18) 0.22 0.61 
CPDT (leg) 97 0.15 (-0.32 to 0.62) 0.53 0.72 
CPDTT (arm) 91 0.43 (-0.01 to 0.86) 0.07 0.42 
Table 1: Imipramine in supine position: Interaction of baseline parameters with the effect of 648 
imipramine on pain (NRS) at 120 min. A positive interaction term indicates a positive 649 
influence on the effect of imipramine compared to placebo. Adjusted p-values are corrected 650 
for multiple testing and indicate the proportion of false-positive discoveries. LR-test = 651 
likelihood-ratio test, KCNS1 = potassium channel subunit, GCH1 = GTP-cyclohydrolase, 652 
OPRM1 = mu-opioid receptor variant A118G, COMT = catechol-O-methyltransferase, 653 
2D6/2C19/3A5 = cytochrome P450 2D6, 2C19, 3A5. T20 = electrical train-of-twenty 654 
stimulation. HPDT/HPTT = heat pain detection/tolerance threshold, CPDT = cold pain 655 
detection threshold, BMI = body mass index, CPM = conditioned pain modulation, 656 
PPDT/PPTT = pressure pain detection/tolerance thresholds, ESPT/ERPT = electrical single 657 
and repeated pain threshold, Iwsec = time in seconds during cold pressor test until cold pain 658 
reaches 7/10 on the numeric rating scale. 659 
  660 
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Table 2 661 
 
No. of 
observations 
Interaction with drug 
effect 
P-value from LR 
test 
Adjusted p-
value 
Sex 98  0.96 0.96 
    male 36 0 (Ref)   
    female 62 -0.02 (-0.84 to 0.80)   
Operated due to pain 96  0.33 0.50 
    no 77 0 (Ref)   
    yes 19 -0.48 (-1.44 to 0.48)   
KCNS1 98  0.75 0.86 
    low pain risk 21 0 (Ref)   
    medium pain risk 56 -0.37 (-1.38 to 0.63)   
    high pain risk 21 -0.38 (-1.55 to 0.78)   
GCH1 98  0.22 0.39 
    no pain protect 74 0 (Ref)   
    one pain protect 18 0.88 (-0.12 to 1.88)   
    both pain protect 6 0.49 (-1.13 to 2.10)   
OPRM1 98  0.047 0.16 
    homozygous wild 66 0 (Ref)   
    1/2 mutant allele 32 0.84 (0.03 to 1.66)   
COMT 98  0.05 0.16 
    low pain sensitivity 12 0 (Ref)   
    average pain sensitivity 76 -0.02 (-1.24 to 1.20)   
    high pain sensitivity 10 1.51 (-0.09 to 3.11)   
2D6 98  0.79 0.86 
    poor metabolizer 6 0 (Ref)   
    intermediate metabolizer 39 0.37 (-1.45 to 2.19)   
    extensive metabolizer 51 0.69 (-1.03 to 2.42)   
    ultrarapid metabolizer 2 0.49 (-2.62 to 3.60)   
2C19 98  0.46 0.60 
    poor metabolizer 2 0 (Ref)   
    intermediate metabolizer 20 -1.61 (-4.44 to 1.21)   
    extensive metabolizer 76 -1.72 (-4.45 to 1.00)   
3A5 98  0.17 0.37 
    low expressors 81 0 (Ref)   
    normal/high expressors 17 0.72 (-0.30 to 1.74)   
T20 decreasers 98  0.41 0.58 
    No decrease 89 0 (Ref)   
    Decrease 9 -0.65 (-2.20 to 0.90)   
Baseline HPTT (leg) at limit 97  0.006 0.027 
    No 58 0 (Ref)   
    Yes 39 -1.18 (-1.96 to -0.39)   
Baseline HPTT (arm) at limit 91  <0.001 0.001 
    No 70 0 (Ref)   
    Yes 21 -1.93 (-2.81 to -1.05)   
Baseline CPDT (leg) at limit 97  0.005 0.027 
    No 52 0 (Ref)   
    yes 45 -1.20 (-2.00 to -0.39)   
32 
 
Baseline CPDT (arm) at limit 91  <0.001 0.002 
    no 65 0 (Ref)   
    yes 26 -1.72 (-2.55 to -0.89)   
Age 98 0.21 (-0.19 to 0.60) 0.30 0.47 
BMI 98 -0.25 (-0.63 to 0.13) 0.20 0.39 
Pain duration 98 -0.36 (-0.73 to 0.02) 0.07 0.18 
Average pain in the last 24h 98 -0.34 (-0.73 to 0.04) 0.09 0.23 
Impairment of daily life 98 -0.01 (-0.40 to 0.38) 0.96 0.96 
Catastrophizing score 98 0.02 (-0.37 to 0.41) 0.93 0.96 
Beck Depression Index 98 0.24 (-0.15 to 0.62) 0.23 0.39 
CPM 97 -0.14 (-0.56 to 0.28) 0.52 0.65 
PPDT 98 -0.44 (-0.83 to -0.05) 0.030 0.12 
PPTT 98 -0.17 (-0.57 to 0.23) 0.41 0.58 
ESPT 98 -0.35 (-0.76 to 0.07) 0.11 0.26 
ERPT 98 -0.28 (-0.71 to 0.14) 0.19 0.39 
Iwsec 97 -0.24 (-0.63 to 0.16) 0.24 0.39 
HPDT (leg) 97 -0.69 (-1.07 to -0.30) 0.001 0.009 
HPDT (arm) 91 -0.80 (-1.16 to -0.43) <0.001 0.001 
HPTT (leg) 97 -0.32 (-0.73 to 0.09) 0.13 0.31 
HPTT (arm) 91 -0.49 (-0.90 to -0.08) 0.021 0.09 
CPDT (leg) 97 0.59 (0.20 to 0.99) 0.005 0.027 
CPDTT (arm) 91 0.80 (0.43 to 1.17) <0.001 0.001 
Table 2: Imipramine in sitting position: Interaction of baseline parameters with the effect of 662 
imipramine on pain (NRS) at 120 min. A positive interaction term indicates a positive 663 
influence on the effect of imipramine compared to placebo.  664 
 665 
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Table 3 667 
 
No. of 
observations 
Interaction with drug 
effect 
P-value from LR 
test 
Adjusted p-
value 
Sex 97  0.15 0.84 
    male 40 0 (Ref)   
    female 57 0.55 (-0.19 to 1.29)   
Operated due to pain 95  0.49 0.94 
    no 79 0 (Ref)   
    yes 16 -0.33 (-1.27 to 0.61)   
KCNS1 97  0.14 0.84 
    low pain risk 18 0 (Ref)   
    medium pain risk 46 -0.76 (-1.73 to 0.21)   
    high pain risk 33 -0.04 (-1.06 to 0.99)   
GCH1 97  0.85 0.94 
    no pain protect 75 0 (Ref)   
    one pain protect 20 -0.24 (-1.18 to 0.70)   
    both pain protect 2 0.37 (-2.20 to 2.94)   
OPRM1 97  0.32 0.84 
    homozygous wild 66 0 (Ref)   
    1/2 mutant allele 31 0.41 (-0.39 to 1.20)   
COMT 97  0.91 0.94 
    low pain sensitivity 8 0 (Ref)   
    average pain sensitivity 81 0.29 (-1.10 to 1.69)   
    high pain sensitivity 8 0.34 (-1.45 to 2.13)   
2D6 97  0.28 0.84 
    poor metabolizer 6 0 (Ref)   
    intermediate metabolizer 36 -1.31 (-2.90 to 0.29)   
    extensive metabolizer 55 -1.16 (-2.72 to 0.40)   
    ultrarapid metabolizer 0    
2C19 97  0.86 0.94 
    poor metabolizer 0    
    intermediate metabolizer 32 0 (Ref)   
    extensive metabolizer 65 -0.07 (-0.89 to 0.74)   
3A5 97  0.81 0.94 
    low expressors 82 0 (Ref)   
    normal/high expressors 15 0.13 (-0.96 to 1.23)   
T20 decreasers 95  0.38 0.94 
    No decrease 83 0 (Ref)   
    Decrease 12 -0.62 (-2.00 to 0.75)   
Baseline HPTT (leg) at limit 97  0.011 0.20 
    No 60 0 (Ref)   
    Yes 37 -1.10 (-1.90 to -0.29)   
Baseline HPTT (arm) at limit 92  0.007 0.20 
    No 69 0 (Ref)   
    Yes 23 -1.23 (-2.10 to -0.36)   
Baseline CPDT (leg) at limit 97  0.22 0.84 
    No 51 0 (Ref)   
    yes 46 -0.50 (-1.29 to 0.30)   
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Baseline CPDT (arm) at limit 92  0.49 0.94 
    no 60 0 (Ref)   
    yes 32 -0.32 (-1.22 to 0.58)   
Age 97 -0.20 (-0.56 to 0.16) 0.28 0.84 
BMI 97 -0.10 (-0.50 to 0.30) 0.63 0.94 
Pain duration 95 0.11 (-0.29 to 0.52) 0.58 0.94 
Average pain in the last 24h 97 0.20 (-0.18 to 0.58) 0.30 0.84 
Impairment of daily life 97 -0.20 (-0.57 to 0.16) 0.29 0.84 
Catastrophizing score 97 -0.09 (-0.47 to 0.29) 0.64 0.94 
Beck Depression Index 97 -0.06 (-0.43 to 0.31) 0.76 0.94 
CPM 94 0.08 (-0.34 to 0.50) 0.70 0.94 
PPDT 97 0.14 (-0.23 to 0.52) 0.45 0.94 
PPTT 97 -0.06 (-0.44 to 0.32) 0.76 0.94 
ESPT 95 -0.00 (-0.43 to 0.43) 0.99 0.99 
ERPT 95 -0.13 (-0.58 to 0.31) 0.55 0.94 
Iwsec 94 -0.02 (-0.40 to 0.36) 0.92 0.94 
HPDT (leg) 97 -0.40 (-0.80 to 0.00) 0.05 0.68 
HPDT (arm) 92 -0.08 (-0.50 to 0.33) 0.69 0.94 
HPTT (leg) 97 -0.24 (-0.68 to 0.20) 0.30 0.84 
HPTT (arm) 92 -0.09 (-0.49 to 0.31) 0.66 0.94 
CPDT (leg) 97 0.06 (-0.34 to 0.45) 0.78 0.94 
CPDTT (arm) 92 0.06 (-0.34 to 0.47) 0.76 0.94 
 668 
Table 3: Clobazam in sitting position: Interaction of baseline parameters with the effect of 669 
clobazam on pain (NRS) at 120 min. A positive interaction term indicates a positive influence 670 
on the effect of clobazam compared to placebo.  671 
  672 
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Supplementary table S1 673 
 
No. of 
observations 
Interaction with drug 
effect 
p-value from LR 
test 
Adjusted p-
value 
Sex 97  0.57 0.94 
    male 45 0 (Ref)   
    female 52 0.29 (-0.71 to 1.29)   
Surgery due to pain 97  0.29 0.86 
    no 79 0 (Ref)   
    yes 18 0.72 (-0.60 to 2.04)   
KCNS1 97  0.27 0.86 
    low pain risk 23 0 (Ref)   
    medium pain risk 52 0.22 (-0.99 to 1.43)   
    high pain risk 22 -0.80 (-2.25 to 0.66)   
GCH1 97  0.58 0.94 
    no pain protect 71 0 (Ref)   
    one pain protect 22 0.39 (-0.79 to 1.56)   
    both pain protect 4 1.14 (-1.34 to 3.61)   
OPRM1 97  0.30 0.86 
    homozygous wt 65 0 (Ref)   
    1/2 mutant allele 32 -0.56 (-1.61 to 0.49)   
COMT 97  0.13 0.86 
    low pain sens 14 0 (Ref)   
    average pain sens 74 1.33 (-0.04 to 2.69)   
    high pain senss 9 1.80 (-0.23 to 3.83)   
2D6 97  0.97 0.97 
    poor metabol 10 0 (Ref)   
    intermediate metabol 39 -0.02 (-1.75 to 1.71)   
    extensive metabol 44 0.15 (-1.57 to 1.88)   
    ultrarapid metabol 4 -0.45 (-3.34 to 2.43)   
2C19 97  0.80 0.94 
    poor metabol 0    
    intermediate metabol 24 0 (Ref)   
    extensive metabol 73 -0.16 (-1.33 to 1.02)   
3A5 97  0.23 0.86 
    low expressors 79 0 (Ref)   
    normal/high expressors 18 -0.80 (-2.08 to 0.49)   
T20 decreasers 97  0.95 0.97 
    max=end 79 0 (Ref)   
    end<max 18 -0.05 (-1.42 to 1.33)   
Baseline HPTT (leg) at limit 97  0.73 0.94 
    no 51 0 (Ref)   
    yes 46 0.18 (-0.85 to 1.20)   
Baseline HPTT (arm) at limit 93  0.16 0.86 
    no 63 0 (Ref)   
    yes 30 -0.81 (-1.94 to 0.31)   
Baseline CPDT (leg) at limit 97  0.94 0.97 
    no 50 0 (Ref)   
    yes 47 0.04 (-1.01 to 1.09)   
Baseline CPDT (arm) at limit 93  0.96 0.97 
    no 65 0 (Ref)   
    yes 28 -0.03 (-1.19 to 1.12)   
Age (per decade) 97 0.05 (-0.29 to 0.38) 0.79 0.94 
BMI 95 0.03 (-0.09 to 0.15) 0.60 0.94 
Pain duration 95 -0.01 (-0.05 to 0.04) 0.77 0.94 
Average pain in the last 24h 95 0.50 (0.16 to 0.84) 0.005 0.20 
Impairment of daily life 95 0.29 (-0.14 to 0.71) 0.19 0.86 
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No. of 
observations 
Interaction with drug 
effect 
p-value from LR 
test 
Adjusted p-
value 
Catastrophizing score 95 0.45 (0.06 to 0.84) 0.027 0.52 
Beck Depression Index 95 0.21 (-0.00 to 0.42) 0.06 0.74 
CPM 97 -0.13 (-0.68 to 0.41) 0.63 0.94 
PPDT 97 -0.30 (-1.67 to 1.07) 0.67 0.94 
PPTT 97 0.51 (-1.22 to 2.24) 0.57 0.94 
ESPT 97 -0.57 (-1.61 to 0.46) 0.28 0.86 
ERPT 97 -0.43 (-1.46 to 0.60) 0.42 0.94 
Iwsec 97 0.12 (-0.61 to 0.85) 0.75 0.94 
HPDT (leg) 97 0.04 (-0.12 to 0.21) 0.59 0.94 
HPDT (arm) 93 -0.03 (-0.15 to 0.09) 0.60 0.94 
HPTT (leg) 97 0.18 (-0.19 to 0.55) 0.35 0.94 
HPTT (arm) 93 0.04 (-0.21 to 0.28) 0.78 0.94 
CPDT (leg) 97 -0.02 (-0.07 to 0.03) 0.38 0.94 
CPDTT (arm) 93 -0.01 (-0.06 to 0.04) 0.70 0.94 
 674 
Supplementary table S1: Oxycodone in supine position: Interaction of baseline parameters 675 
with the effect of oxycodone on pain (NRS) at 120 min. A positive interaction term indicates 676 
a positive influence on the effect of oxycodone compared to placebo.  677 
 678 
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Supplementary table S2 680 
 
No. of 
observations 
Interaction with drug 
effect 
p-value from 
LR test 
Adjusted p-
value 
Sex 98  0.09 0.98 
    male 46 0 (Ref)   
    female 52 0.83 (-0.11 to 1.77)   
Surgery due to pain 98  0.18 0.98 
    no 79 0 (Ref)   
    yes 19 0.89 (-0.41 to 2.18)   
KCNS1 98  0.83 0.98 
    low pain risk 23 0 (Ref)   
    medium pain risk 51 0.16 (-1.05 to 1.37)   
    high pain risk 24 -0.21 (-1.61 to 1.20)   
GCH1 98  0.78 0.98 
    no pain protect 72 0 (Ref)   
    one pain protect 22 0.13 (-1.03 to 1.29)   
    both pain protect 4 0.87 (-1.59 to 3.33)   
OPRM1 98  0.26 0.98 
    homozygous wt 66 0 (Ref)   
    1/2 mutant allele 32 -0.59 (-1.61 to 0.42)   
COMT 98  0.81 0.98 
    low pain sens 16 0 (Ref)   
    average pain sens 73 -0.15 (-1.47 to 1.16)   
    high pain senss 9 0.40 (-1.60 to 2.40)   
2D6 98  0.44 0.98 
    poor metabol 10 0 (Ref)   
    intermediate metabol 41 0.89 (-0.75 to 2.53)   
    extensive metabol 43 1.28 (-0.38 to 2.94)   
    ultrarapid metabol 4 0.18 (-2.58 to 2.95)   
2C19 98  1.00 1.00 
    poor metabol 0 0 (Ref)   
    intermediate metabol 24    
    extensive metabol 74 0.00 (-1.14 to 1.14)   
3A5 98  1.00 1.00 
    low expressors 80 0 (Ref)   
    normal/high expressors 18 -0.00 (-1.26 to 1.26)   
T20 decreasers 98  0.20 0.98 
    max=end 81 0 (Ref)   
    end<max 17 0.88 (-0.44 to 2.20)   
Baseline HPTT (leg) at limit 97  0.51 0.98 
    no 51 0 (Ref)   
    yes 46 0.34 (-0.66 to 1.33)   
Baseline HPTT (arm) at limit 93  0.28 0.98 
    no 63 0 (Ref)   
    yes 30 0.61 (-0.48 to 1.71)   
Baseline CPDT (leg) at limit 97  0.94 1.00 
    no 49 0 (Ref)   
    yes 48 0.04 (-0.99 to 1.07)   
Baseline CPDT (arm) at limit 93  0.89 0.99 
    no 65 0 (Ref)   
    yes 28 0.08 (-1.05 to 1.22)   
Age (per decade) 98 -0.12 (-0.44 to 0.20) 0.45 0.98 
BMI 96 -0.07 (-0.18 to 0.05) 0.26 0.98 
Pain duration 96 -0.01 (-0.05 to 0.04) 0.80 0.98 
Average pain in the last 24h 96 0.14 (-0.20 to 0.49) 0.42 0.98 
Impairment of daily life 96 -0.21 (-0.63 to 0.22) 0.34 0.98 
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No. of 
observations 
Interaction with drug 
effect 
p-value from 
LR test 
Adjusted p-
value 
Catastrophizing score 96 -0.12 (-0.52 to 0.28) 0.56 0.98 
Beck Depression Index 96 -0.09 (-0.30 to 0.12) 0.38 0.98 
CPM 98 -0.16 (-0.67 to 0.36) 0.56 0.98 
PPDT 98 -0.20 (-1.55 to 1.15) 0.77 0.98 
PPTT 98 -0.03 (-1.74 to 1.67) 0.97 1.00 
ESPT 98 -0.26 (-1.27 to 0.75) 0.61 0.98 
ERPT 98 -0.09 (-1.10 to 0.92) 0.86 0.99 
Iwsec 98 0.20 (-0.50 to 0.91) 0.57 0.98 
HPDT (leg) 97 0.05 (-0.11 to 0.21) 0.51 0.98 
HPDT (arm) 93 0.04 (-0.08 to 0.16) 0.51 0.98 
HPTT (leg) 97 0.05 (-0.32 to 0.42) 0.78 0.98 
HPTT (arm) 93 0.09 (-0.15 to 0.33) 0.45 0.98 
CPDT (leg) 97 -0.02 (-0.06 to 0.03) 0.49 0.98 
CPDTT (arm) 93 -0.02 (-0.07 to 0.03) 0.43 0.98 
Supplementary table S2: Oxycodone in sitting position: Interaction of baseline parameters 681 
with the effect of oxycodone on pain (NRS) at 120 min. A positive interaction term indicates 682 
a positive influence on the effect of oxycodone compared to placebo.  683 
 684 
  685 
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Supplementary table S3 686 
 
No. of 
observations 
Interaction with drug 
effect 
p-value from LR 
test 
Adjusted p-
value 
Sex 94  0.80 0.90 
    male 37 0 (Ref)   
    female 57 0.12 (-0.80 to 1.04)   
Surgery due to pain 92  0.27 0.71 
    no 76 0 (Ref)   
    yes 16 0.66 (-0.50 to 1.81)   
KCNS1 94  0.007 0.12 
    low pain risk 18 0 (Ref)   
    medium pain risk 46 -0.57 (-1.65 to 0.50)   
    high pain risk 30 0.98 (-0.18 to 2.13)   
GCH1 94  0.23 0.71 
    no pain protect 72 0 (Ref)   
    one pain protect 20 -0.91 (-1.97 to 0.14)   
    both pain protect 2 0.38 (-2.63 to 3.40)   
OPRM1 94  0.85 0.90 
    homozygous wt 66 0 (Ref)   
    1/2 mutant allele 28 0.09 (-0.88 to 1.06)   
COMT 94  0.84 0.90 
    low pain sens 8 0 (Ref)   
    average pain sens 78 -0.50 (-2.17 to 1.17)   
    high pain senss 8 -0.45 (-2.59 to 1.70)   
2D6 94  0.26 0.71 
    poor metabol 6 0 (Ref)   
    intermediate metabol 36 -1.00 (-2.88 to 0.88)   
    extensive metabol 52 -0.27 (-2.10 to 1.56)   
    ultrarapid metabol 0    
2C19 94  0.40 0.83 
    poor metabol 0    
    intermediate metabol 32 0 (Ref)   
    extensive metabol 62 0.42 (-0.56 to 1.39)   
3A5 94  0.32 0.71 
    low expressors 82 0 (Ref)   
    normal/high expressors 12 -0.71 (-2.13 to 0.70)   
T20 decreasers 92  0.24 0.71 
    max=end 81 0 (Ref)   
    end<max 11 -0.88 (-2.33 to 0.56)   
Baseline HPTT (leg) at limit 94  0.11 0.71 
    no 57 0 (Ref)   
    yes 37 -0.78 (-1.71 to 0.15)   
Baseline HPTT (arm) at limit 89  0.29 0.71 
    no 66 0 (Ref)   
    yes 23 -0.57 (-1.60 to 0.46)   
Baseline CPDT (leg) at limit 94  0.64 0.87 
    no 50 0 (Ref)   
    yes 44 -0.22 (-1.15 to 0.70)   
Baseline CPDT (arm) at limit 89  0.82 0.90 
    no 58 0 (Ref)   
    yes 31 -0.11 (-1.12 to 0.89)   
Age (per decade) 94 -0.09 (-0.38 to 0.20) 0.53 0.84 
BMI 94 0.02 (-0.08 to 0.12) 0.75 0.90 
Pain duration 92 -0.00 (-0.05 to 0.04) 0.85 0.90 
Average pain in the last 24h 94 0.23 (-0.01 to 0.46) 0.06 0.70 
Impairment of daily life 94 0.01 (-0.31 to 0.33) 0.97 0.97 
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No. of 
observations 
Interaction with drug 
effect 
p-value from LR 
test 
Adjusted p-
value 
Catastrophizing score 94 0.12 (-0.22 to 0.46) 0.48 0.84 
Beck Depression Index 94 0.04 (-0.15 to 0.24) 0.66 0.87 
CPM 91 0.13 (-0.28 to 0.54) 0.54 0.84 
PPDT 94 -0.46 (-1.68 to 0.77) 0.47 0.84 
PPTT 94 -0.93 (-2.27 to 0.41) 0.18 0.71 
ESPT 92 0.55 (-0.35 to 1.45) 0.24 0.71 
ERPT 92 0.48 (-0.47 to 1.44) 0.33 0.71 
Iwsec 91 -0.15 (-0.81 to 0.51) 0.66 0.87 
HPDT (leg) 94 -0.16 (-0.33 to 0.01) 0.08 0.70 
HPDT (arm) 89 -0.03 (-0.14 to 0.08) 0.64 0.87 
HPTT (leg) 94 -0.30 (-0.68 to 0.09) 0.14 0.71 
HPTT (arm) 89 -0.09 (-0.30 to 0.13) 0.44 0.84 
CPDT (leg) 94 0.00 (-0.04 to 0.05) 0.97 0.97 
CPDTT (arm) 89 0.01 (-0.03 to 0.06) 0.55 0.84 
 687 
Supplementary table S3: Clobazam in supine position: Interaction of baseline parameters with 688 
the effect of clobazam on pain (NRS) at 120 min. A positive interaction term indicates a 689 
positive influence on the effect of clobazam compared to placebo.  690 
 691 
  692 
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Supplementary table S4 693 
Gene SNP Allele Frequency n(%) Hardy Weinberg Χ2 p-value 
   11 12 22   
KCNS1  rs734784 28 (31%) 42 (47%) 20 (22%) 0.32 0.57 
        
GCH-1  rs8007267 4 (5%) 22 (24%) 64 (71%) 1.30 0.25 
  rs3783641 61 (67%) 24 (27%) 5 (6%) 1.51 0.21 
  rs10483639 62 (68%) 23 (26%) 5 (6%) 1.93 0.16 
        
OPRM A118G rs1799971 58 (65%) 30 (33%) 2 (2%) 0.69 0.4 
        
COMT  rs6269  12 (13%) 47 (53%) 31 (34%) 0.78 0.37 
  rs4633 20 (22%) 50 (56%) 20 (22%) 1.11 0.29 
  rs4818 33 (37%) 45 (50%) 12 (13%) 0.30 0.58 
  rs46801 20 (22%) 49 (56%) 20 (22%) 0.91 0.34 
        
CYP3A 3A4*1b rs2740574 83 (92%) 7 (8%) - 0.15 0.70 
 3A5*3 rs776746 1 (1%) 14 (16%) 75 (83%) 0.14 0.70 
        
CYP2D6 CYP2D6*6 rs5030655 90 (100%) - - n/a - 
 CYP2D6*8 rs5030865 90 (100%) - - n/a - 
 CYP2D6*10 rs1065852 53 (59%) 32 (35%) 5 (6%) 0.06 0.95 
 CYP2D6*41 rs283717251 76 (85%) 12 (14%) 1 (1%) 0.43 0.51 
 CYP2D6*3A rs35742686 86 (96%) 3 (3%) 1 (1%) 13.2 <0.001 
 CYP2D6*4 rs3892097 57 (63%) 28 (31%) 5 (6%) 0.39 0.53 
 CYP2D6*5  Gene deletion Normal: 82 (91%) Deleted: 8 (9%) n/a - 
 CYP2D6*2  Gene multiplication Normal: 87 (97%) Multiple: 3 (3%) n/a - 
        
CYP2C19 CYP2C19*2 rs4244285 68 (76%) 21 (23%) 1 (1%) 0.20 0.66 
 CYP2C19*3 Rs4986893 90 (100%) - - n/a - 
Supplementary table S4: Allele frequencies for each of the genotyped single-nucleotide polymorphisms (n=90). KCNS1 = Potassium voltage-gated channel 694 
subfamily S member 1, GCH-1 = GTP-Cyclohydrolase, OPRM = mu opioid receptor, COMT = catechol-O-methyltransferase, CYP = Cytochrome P450. 1One 695 
missing value (n=89)  696 
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Figure 1 697 
 698 
Figure 1: Effect of imipramine versus placebo in sitting position. A positive number indicates 699 
a positive effect (i.e. a decrease in pain). Imipramine is more effective in cold/heat sensitive 700 
patients. Two patients had missing values for pain in the imipramine phase. NRS = numeric 701 
rating scale, HPTT = heat pain tolerance threshold, CPDT = cold pain detection threshold. 702 
 703 
 704 
  705 
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Figure 2 706 
 707 
Figure 2: Effect of imipramine versus placebo in supine position. A positive number indicates 708 
a positive effect (i.e. a decrease in pain). There is a trend towards better effect of imipramine 709 
in heat-sensitive patients. Two patients had missing values for pain in the imipramine phase. 710 
 711 
 712 
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Figure 3 714 
 715 
Figure 3: Effect of clobazam versus placebo in sitting position. A positive number indicates a 716 
positive effect (i.e. a decrease in pain). One patient had missing values for pain in the placebo 717 
phase. 718 
 719 
